Drug Trial Radar · NCT07935356
A Phase 3 Evaluation of Sutacimig in Glanzmann Thrombasthenia
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
76
Planned (sponsor's estimate)
Start
Oct 27, 2026
Primary completion
Nov 2029
Study completion Jan 2030
Sponsor
- Lead sponsor
- Hemab ApSIndustry
- Sponsor type
- Industry
- First posted
- Nov 13, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Glanzmann thrombasthenia (GT) is a serious inherited bleeding disorder. In GT, platelets, the blood cells that normally stick together at the site of an injury to stop bleeding, are unable to properly do so. As a result, bleeding does not stop as it should. Bleeding in GT often starts without warning, can happen frequently, and can be severe. It most commonly affects the nose, mouth and gums, gastrointestinal tract, and skin, and many women and girls with GT experience heavy menstrual bleeding. Over time, bleeding can lead to iron deficiency and anemia. Some bleeding episodes require emergency care, hospitalization, transfusion, or surgery, and some can be life-threatening. Sutacimig is an investigational medicine given as an injection under the skin (subcutaneous injection). It is designed to help platelets work at the site of bleeding despite the underlying defect in GT. It is intended to be given regularly to help prevent bleeding (prophylaxis), rather than only to treat bleeding after it starts. The purpose of this study is to find out whether sutacimig, given as prophylaxis, reduces the number of treated bleeding episodes in people with GT compared with no prophylaxis, and to evaluate its safety and tolerability.
Conditions
- Thrombasthenia
Interventions
SutacimigDrug
Sutacimig will be administered by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Treated Bleed Rate (ATBR)Time frame: From the first dose through Week 48
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California San Diego (UC San Diego) Health - Jacobs Medical Center
La Jolla, California · Not yet recruiting
Children's Hospital Los Angeles
Los Angeles, California · Not yet recruiting
University of California Davis (UC Davis) Medical Center
Sacramento, California · Not yet recruiting
University of California San Francisco (UCSF) Medical Center
San Francisco, California · Not yet recruiting
Innovative Hematology - Indiana Hemophilia & Thrombosis Center
Indianapolis, Indiana · Not yet recruiting
M Health Fairview - University of Minnesota Medical Center
Minneapolis, Minnesota · Not yet recruiting
New York-Presbyterian - Weill Cornell Medical Center
New York, New York · Not yet recruiting
Science 37
Durham, North Carolina · Recruiting
Gulf States Hemophilia and Thrombophilia Center - Texas Medical Center
Houston, Texas · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.